MYGN Myriad Genetics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

MYGN [NASD]

Myriad Genetics, Inc.

Healthcare | Diagnostics & Research | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.68	Insider Own	2.10%	Shs Outstand	74.60M	Perf Week	13.65%
Market Cap	1.10B	Forward P/E	47.90	EPS next Y	0.31	Insider Trans	-0.18%	Shs Float	73.25M	Perf Month	20.74%
Income	-199.50M	PEG	-	EPS next Q	-0.29	Inst Own	-	Short Float	12.81%	Perf Quarter	22.11%
Sales	638.60M	P/S	1.73	EPS this Y	-175.00%	Inst Trans	0.67%	Short Ratio	12.99	Perf Half Y	-4.82%
Book/sh	12.31	P/B	1.19	EPS next Y	236.40%	ROA	-13.30%	Target Price	15.86	Perf Year	-55.31%
Cash/sh	2.88	P/C	5.07	EPS next 5Y	8.10%	ROE	-19.80%	52W Range	9.24 - 35.29	Perf YTD	-46.35%
Dividend	-	P/FCF	21.85	EPS past 5Y	-35.10%	ROI	-18.20%	52W High	-58.60%	Beta	1.47
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	-2.50%	Gross Margin	70.90%	52W Low	58.12%	ATR	0.55
Employees	2700	Current Ratio	2.30	Sales Q/Q	-56.70%	Oper. Margin	-36.30%	RSI (14)	63.91	Volatility	3.98% 3.90%
Optionable	Yes	Debt/Eq	0.24	EPS Q/Q	-	Profit Margin	-31.20%	Rel Volume	0.77	Prev Close	14.67
Shortable	Yes	LT Debt/Eq	0.24	Earnings	Aug 13 AMC	Payout	-	Avg Volume	722.33K	Price	14.61
Recom	3.10	SMA20	11.08%	SMA50	10.00%	SMA200	-5.40%	Volume	554,996	Change	-0.41%

Sep-26-19

Downgrade

BofA/Merrill

Neutral → Underperform

$30 → $28

Aug-14-19

Downgrade

Piper Jaffray

Overweight → Neutral

$45 → $40

Aug-02-19

Upgrade

BofA/Merrill

Underperform → Neutral

Aug-01-19

Upgrade

Barclays

Underweight → Equal Weight

$18 → $40

Jul-29-19

Downgrade

Needham

Strong Buy → Hold

Jul-09-19

Downgrade

Cowen

Outperform → Market Perform

Mar-12-19

Reiterated

Needham

Strong Buy

$37 → $41

Jan-03-19

Initiated

Needham

Strong Buy

$36

Nov-30-18

Upgrade

Goldman

Sell → Neutral

Oct-10-18

Upgrade

Piper Jaffray

Neutral → Overweight

Jul-11-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Mar-21-18

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Jan-29-18

Initiated

Goldman

Sell

$32

Jan-22-18

Reiterated

Barclays

Equal Weight

$30 → $35

Jan-05-18

Initiated

BTIG Research

Buy

$41

Oct-02-17

Resumed

Leerink Partners

Mkt Perform

$31

Aug-09-17

Reiterated

Barclays

Equal Weight

$28 → $26

Feb-08-17

Upgrade

Ladenburg Thalmann

Sell → Neutral

Jan-18-17

Initiated

Deutsche Bank

Sell

$15

Oct-10-16

Downgrade

Ladenburg Thalmann

Neutral → Sell

Oct-16-20 09:05AM	German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test GlobeNewswire
Oct-15-20 07:05AM	Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests GlobeNewswire
Oct-05-20 12:11PM	Here is What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Sep-16-20 10:58AM	Insider Sells Myriad Genetics Stock Benzinga
Sep-12-20 11:30AM	Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-10-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member GlobeNewswire
Sep-03-20 06:21PM	Analyst Report: Myriad Genetics, Inc. Morningstar Research -7.42%
Aug-24-20 11:04AM	ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer Zacks
Aug-21-20 07:05AM	American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer GlobeNewswire
Aug-14-20 04:05PM	Myriad Genetics Announces Inducement Awards GlobeNewswire -5.38%
10:46AM	Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated Zacks
06:36AM	COVID-19 Pandemic Wreaks Havoc on Myriad Genetics' Fiscal Q4 Results Motley Fool
12:30AM	Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript Motley Fool
Aug-13-20 06:15PM	Myriad Genetics (MYGN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:19PM	Recap: Myriad Genetics Q4 Earnings Benzinga
04:08PM	Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors GlobeNewswire
04:07PM	Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results GlobeNewswire
Aug-12-20 11:01AM	Preview: Myriad Genetics's Earnings Benzinga +5.15%
Aug-10-20 07:05AM	New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions GlobeNewswire
Aug-06-20 07:05AM	Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020 GlobeNewswire
Aug-04-20 12:30PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-31-20 07:05AM	Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer GlobeNewswire
Jul-29-20 07:05AM	Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test GlobeNewswire
Jul-28-20 07:05AM	Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra® GlobeNewswire
Jul-22-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. GlobeNewswire
Jul-07-20 06:32PM	Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge Zacks
07:05AM	Myriad Announces New Studies Validating the Ability of Myriads riskScore® Test to Modify Breast Cancer Risk Prediction GlobeNewswire
Jul-06-20 10:04AM	Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis Zacks
07:05AM	Myriad Announces Partnership with OptraHEALTH® to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients GlobeNewswire
Jul-05-20 08:56PM	Hedge Funds Never Been Less Bullish On Myriad Genetics, Inc. (MYGN) Insider Monkey
Jul-02-20 08:46AM	Myriad Genetics Unveils New Home DNA Sample Collection Kit Zacks
Jul-01-20 07:05AM	Myriad Launches New GeneSight® Psychotropic Patient Collection Kit GlobeNewswire
Jun-29-20 11:27AM	Myriad Genetics' myPath Melanoma Proved Superior Per New Study Zacks
Jun-25-20 07:05AM	New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment GlobeNewswire
Jun-23-20 11:19AM	Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger Zacks
Jun-22-20 10:32AM	4 Toxic Stocks to Disown or Play Short to Book Profits Zacks
Jun-17-20 11:53AM	Myriad Genetics' Prolaris Receives Favorable Coverage Policies Zacks
Jun-15-20 07:05AM	Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider GlobeNewswire +5.83%
Jun-12-20 07:48PM	Edited Transcript of MYGN earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-11-20 02:22PM	Here's Why Myriad Genetics Is Tumbling Today Motley Fool -20.92%
11:24AM	Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries GlobeNewswire
Jun-09-20 10:23AM	Myriad Genetics' Test Better Predicts Drug Levels Per Study Zacks
Jun-08-20 07:05AM	New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing GlobeNewswire
Jun-05-20 09:00AM	Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses Zacks
Jun-04-20 11:31AM	Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report? Zacks
07:05AM	Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer GlobeNewswire
May-29-20 07:05AM	Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients GlobeNewswire
May-28-20 07:05AM	Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. GlobeNewswire
May-27-20 11:14AM	Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories Zacks
May-26-20 09:27AM	Dump These 4 Toxic Stocks or Sell Short for Timely Profits Zacks
07:00AM	Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study GlobeNewswire
May-20-20 08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
07:05AM	Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
May-18-20 11:55AM	Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem Zacks
May-13-20 05:26PM	Biotech ETFs to Gain From Latest Advancements in Cancer Drugs Zacks
May-11-20 07:05AM	Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza (olaparib) In Patients with Advanced Ovarian Cancer GlobeNewswire +8.89%
May-06-20 11:49AM	Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View Zacks
May-05-20 11:01PM	Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript Motley Fool
04:05PM	Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results GlobeNewswire
Apr-28-20 04:05PM	Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 GlobeNewswire
12:33PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-20-20 07:05AM	Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder GlobeNewswire
Apr-08-20 07:05AM	Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic GlobeNewswire
Apr-07-20 11:35AM	Hedge Funds Are Buying Myriad Genetics, Inc. (MYGN) Insider Monkey
09:32AM	Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement Zacks
Apr-06-20 07:05AM	Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC GlobeNewswire +25.16%
Mar-30-20 07:05AM	Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer GlobeNewswire
Mar-23-20 07:13AM	A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN) Simply Wall St.
07:05AM	Myriad Announces Board of Directors Leadership Transition GlobeNewswire
Mar-19-20 09:46AM	Myriad Grows Internationally, Hereditary Cancer Revenues Soft Zacks +24.13%
Mar-18-20 07:05AM	NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer GlobeNewswire -5.42%
Mar-07-20 11:31AM	Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-04-20 08:29AM	Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems Zacks +5.74%
Mar-03-20 09:28AM	Dump These 5 Toxic Stocks Right Away Zacks -7.42%
Feb-28-20 06:58AM	The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher Zacks
Feb-17-20 04:02PM	Edited Transcript of MYGN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
09:31AM	Steer Clear Of These 5 Toxic Stocks Before It's Too Late Zacks
07:46AM	Myriad Genetics (MYGN) Releases Favorable Prolaris Results Zacks
Feb-14-20 07:05AM	New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy GlobeNewswire
Feb-13-20 10:36AM	Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA Zacks
Feb-12-20 07:05AM	Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-11-20 07:05AM	Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer GlobeNewswire
Feb-07-20 08:08PM	The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN) Business Wire -28.23%
09:56AM	Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates Zacks
08:58AM	Myriad Genetics Stock Is Tanking After Earnings. The CEO Is Out. Barrons.com
07:32AM	The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
07:23AM	What Did Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Take Home Last Year? Simply Wall St.
Feb-06-20 06:15PM	Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates Zacks
04:05PM	Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results GlobeNewswire
04:05PM	Myriad Announces Leadership Transition GlobeNewswire
02:30PM	Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
Jan-30-20 07:05AM	Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020 GlobeNewswire
Jan-28-20 12:31PM	Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline Zacks
Jan-22-20 06:36PM	Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer GlobeNewswire
Jan-21-20 07:05AM	Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer GlobeNewswire
Jan-14-20 07:05AM	Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology GlobeNewswire
Jan-07-20 09:35AM	Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging Zacks
Jan-06-20 04:05PM	Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference GlobeNewswire
07:05AM	New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study GlobeNewswire
Dec-31-19 11:12AM	Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod Zacks

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ford Alexander	Chief Operating Officer	Sep 15	Sale	13.78	2,804	38,630	151,159	Sep 16 09:56 AM
Lambert Nicole	President, MGL	Feb 12	Sale	19.73	4,354	85,915	59,150	Feb 12 06:28 PM
Ford Alexander	President, MWH	Feb 05	Sale	30.00	7,273	218,190	142,438	Feb 07 02:39 PM
Ford Alexander	President, MWH	Dec 26	Option Exercise	15.98	1,307	20,886	149,711	Dec 27 12:47 PM
GILBERT WALTER PHD	Director	Dec 13	Buy	25.60	5,860	149,998	54,150	Dec 16 04:16 PM
HENDERSON JOHN T	Director	Nov 07	Buy	23.46	1,750	41,056	2,050	Nov 07 01:05 PM
HENDERSON JOHN T	Director	Nov 07	Buy	23.46	5,250	123,167	64,353	Nov 07 01:05 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience